98%
921
2 minutes
20
Research designed to establish alcohol and other drug (AOD) mechanisms of behavioral change (MOBC) has centered on what variables mediate the relation between AOD treatment and outcomes. The purpose of this paper was to review this research evidence to identify empirically supported mediators of alcohol and other drug use and related outcomes and then to evaluate their potential as being AOD treatment MOBC. The first phase was a systematic review of reviews (2008-2023) to identify the variables with the strongest empirical support as mediators of AOD treatment effects. Eligible reviews focused on AOD treatment modalities, included empirically tested mediators, and targeted adult samples. The second phase was a systematic review of empirical studies (1990-2023) testing the hypothesis that variables identified in phase one were AOD treatment mediators/mechanisms and then evaluating each eligible stage two study according to the Kazdin and Nock (Journal of Child Psychology and Psychiatry, 44, 1116) criteria. Eligible articles included empirical studies with adult samples attending AOD treatment and empirically tested one of the three treatment mechanisms as a mediator of an AOD-related outcome. Databases were searched in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. This systematic review was not preregistered. The first review of 11 eligible review articles identified self-efficacy, social support, and craving as having the strongest empirical support. The second review captured 48 individual studies. An evaluation of each of these studies by the Kazdin and Nock criteria suggested that they likely are MOBC and therefore are ready for implementation. The implementation of self-efficacy, social support, and craving into clinical practice and training is warranted. Six directions for future research to solidify and generalize empirical support for the case that self-efficacy, social support, and craving are MOBC are presented, as are five implications for clinical practice and training.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/acer.15411 | DOI Listing |
Int J Cancer
September 2025
Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Immune checkpoint inhibitors (ICIs) are effective anti-tumor agents, but new immune-related side effects (irAEs) are emerging. This retrospective cohort study investigated 461 lung cancer patients treated with ICIs over 2 years, analyzing changes in pulmonary artery diameter (PAD), aortic diameter (AoD), and the pulmonary artery/aortic diameter (PAD/AoD) ratio through chest computed tomography (CT) at baseline, 3 months, 6 months, 1 year, and 2 years post-treatment. The PAD increased from 25.
View Article and Find Full Text PDFDrug Alcohol Rev
September 2025
Health Behaviour Research Collaborative, School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, Australia.
Introduction: Understanding the characteristics of individuals seeking treatment for alcohol use is essential for developing effective interventions. This study aimed to: (i) describe the characteristics of individuals accessing treatment at Australian outpatient alcohol and other drug (AOD) treatment centres; and (ii) identify characteristics associated with more harmful alcohol use at treatment commencement.
Methods: Clients from 34 community-based AOD centres completed surveys on demographic, substance use, health-related quality of life and social characteristics.
Drug Alcohol Depend
August 2025
School of Psychology, University of Wollongong, Australia; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
Background: Substance use disorders frequently begin in adolescence and emerging adulthood. Knowledge of trends in alcohol and other drug (AOD) service utilisation during these periods can inform policy development to align service delivery with treatment need.
Aims: Characterise trends in AOD treatment episodes among adolescents (aged 10-17) and emerging adults (aged 18-24) across Australia, and compare to adult trends (aged ≥25).
BMC Public Health
August 2025
School of Psychology, University of Wollongong, Wollongong, NSW, Australia.
Background: People accessing alcohol and other drug (AOD) treatment experience high rates of loneliness, which is a strong driver of substance use. Groups for Belonging is a 6-session group-based intervention that combines elements of the social identity informed intervention Groups for Health with psychoeducation and strategies to help participants manage loneliness and overcome cognitive barriers to social connection. The project will examine the effectiveness and cost-effectiveness of delivering Groups for Belonging within routine care offered by AOD treatment providers in Australia.
View Article and Find Full Text PDFToxins (Basel)
August 2025
Jiangxi Key Laboratory of Aging and Disease, Sphingolipid Metabolism and Aging, Human Aging Research Institute (HARI) and School of Life Science, Nanchang University, Nanchang 330031, China.
2-Amino-14,16-dimethyloctadecan-3-ol (AOD) is commonly found in foods contaminated with , particularly cereals or fruits, and is structurally related to mycotoxins (fumonisins) and mammalian sphingoid bases, especially 1-deoxysphinganine (m18:0); therefore, it might enter systemic circulation and tissues upon dietary intake. Knowledge about what happens when cells are exposed to AOD is limited, but it has been reported to be cytotoxic and to induce vacuolization in HepG2 cells. We also found that AOD is cytotoxic for HepG2 cells, but even at a concentration where cell viability remained above 85% (5 μM), it altered 24 differentially expressed genes based on RNA sequencing-based transcriptomic profiling.
View Article and Find Full Text PDF